- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02403674
Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) (DRIVE-AHEAD)
September 22, 2023 updated by: Merck Sharp & Dohme LLC
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects
The purpose of this study is to compare the antiretroviral activity of doravirine, tenofovir, lamivudine (MK-1439A), a single-tablet, once-daily (q.d.) fixed-dose combination (FDC) containing doravirine (MK-1439) 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, with ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg, in treatment-naive participants infected with human immunodeficiency virus (HIV).
The primary hypothesis is that doravirine, tenofovir, lamivudine q.d. is non-inferior to ATRIPLA™ q.d. as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL (by the Abbott RealTime HIV-1 Assay) at Week 48.
This study has a total duration of 192 weeks, including a 96-week double-blind period and a 96-week open-label period.
The present results are based on the first 48 weeks of this ongoing study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Participants in Australia, Colombia, Guatemala, Honduras, Israel, New Zealand, Peru, Russia, South Africa, and Thailand who are deriving benefit from doravirine, tenofovir, lamivudine are also eligible to continue receiving study drug during additional open-label extensions which will last for 2 years or until drug is available locally, whichever comes first.
Study Type
Interventional
Enrollment (Actual)
734
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Is HIV-1 positive as determined by a positive result on an enzyme-immunoassay, has screening plasma HIV-1 RNA (determined by the central laboratory) ≥1000 copies/mL within 45 days prior to the treatment phase of this study, and has HIV treatment indicated based on physician assessment
- Has never received antiretroviral therapy (ART)
- Is highly unlikely to either become pregnant or impregnate a partner
Exclusion Criteria:
- Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound results of the study
- Is a user of recreational or illicit drugs or has a recent history of alcohol/drug abuse
- Has been treated for a viral infection other than HIV-1 (e.g., hepatitis B) with an agent that is active against HIV-1
- Has participated in a study with an investigational drug/device within 30 days prior to Screening
- Has used systemic immunosuppressive therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study
- Has a current (active) diagnosis of acute hepatitis due to any cause (note: participants with chronic hepatitis B and C may enter the study as long as they fulfill all entry criteria, have stable liver function tests, and have no significant impairment of hepatic synthetic function)
- Is a female who is pregnant, breastfeeding, or expecting to conceive
- Is a female and is expecting to donate eggs or is male and is expecting to donate sperm (investigators will provide appropriate guidance regarding egg and/or sperm donation after completion of the study treatment regimen)
- Has evidence of decompensated liver disease manifested by the presence of or a history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver diseases, or has liver cirrhosis and a Child-Pugh Class C score or Pugh-Turcotte (CPT) score > 9
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Doravirine, Tenofovir, Lamivudine
Treatment-naive HIV-infected participants will receive doravirine, tenofovir, lamivudine, a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for 96 weeks.
Participants will also take 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding.
|
One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.
Other Names:
Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
|
Active Comparator: ATRIPLA™
Treatment-naive HIV-infected participants will receive ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks.
Participants will also take 1 placebo tablet matched to doravirine, tenofovir, lamivudine q.d. by mouth for 96 weeks in order to maintain blinding.
|
Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
One ATRIPLA™ tablet taken q.d. by mouth
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
Time Frame: Week 48
|
The percentage of participants in each arm with HIV-1 RNA levels <50 copies/mL at Week 48 was determined.
Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay.
Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason.
|
Week 48
|
Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs)
Time Frame: Up to Week 48
|
The percentage of participants in each arm experiencing ≥1 pre-specified Tier-1 neuropsychiatric AEs was determined.
The list of Tier-1 neuropsychiatric AE categories included "dizziness", "sleep disorders and disturbances", and "altered sensorium" (including disturbance in attention).
|
Up to Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
Time Frame: Week 96
|
The percentage of participants in each arm with HIV-1 RNA levels <50 copies/mL at Week 96 will be determined.
Plasma HIV-1 RNA levels will be quantified with the Abbott RealTime HIV-1 Assay.
The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) will be used for efficacy analyses.
|
Week 96
|
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48
Time Frame: Week 48
|
The percentage of participants in each arm with HIV-1 RNA levels <40 copies/mL (including target detected and target not detected) at Week 48 was determined.
Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay.
Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason.
|
Week 48
|
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96
Time Frame: Week 96
|
The percentage of participants in each arm with HIV-1 RNA levels <40 copies/mL (including target detected and target not detected) at Week 96 will be determined.
Plasma HIV-1 RNA levels will be quantified with the Abbott RealTime HIV-1 Assay.
The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) will be used for efficacy analyses.
|
Week 96
|
Change From Baseline in CD4 Cell Counts at Week 48
Time Frame: Baseline (Day 1) and Week 48
|
The mean change from baseline in CD4 cell counts at Week 48 was assessed using the Observed Failure (OF) approach.
With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 48 due to lack of efficacy.
Cell counts at Baseline and Week 48 were measured and expressed as cells/mm^3, and percent change was then calculated as [(Baseline counts - Week 48 counts)*100].
CD4 cell counts were quantified by a central laboratory using a commercially available assay.
|
Baseline (Day 1) and Week 48
|
Change From Baseline in CD4 Cell Counts at Week 96
Time Frame: Baseline (Day 1) and Week 96
|
The mean change from baseline in CD4 cell counts at Week 96 will be assessed using the Observed Failure (OF) approach.
With the OF approach, baseline values will be carried forward for participants who discontinued prior to Week 96 due to lack of efficacy.
Cell counts at Baseline and Week 96 will be measured and expressed as cells/mm^3, and percent change will then be calculated as [(Baseline counts - Week 96 counts)*100].
CD4 cell counts will be quantified by a central laboratory using a commercially available assay.
|
Baseline (Day 1) and Week 96
|
Percentage of Participants Experiencing ≥1 AE
Time Frame: Up to Week 48
|
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
|
Up to Week 48
|
Percentage of Participants Discontinuing From Study Medication Due to an AE(s)
Time Frame: Up to Week 48
|
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
|
Up to Week 48
|
Percentage of Participants With Tier-2 Neuropsychiatric AEs
Time Frame: Up to Week 48
|
The percentage of participants in each arm experiencing ≥1 pre-specified Tier-2 neuropsychiatric AEs was determined.
The list of Tier-2 neuropsychiatric AE categories included "depression and suicide/self-injury" and "psychosis and psychotic disorders".
|
Up to Week 48
|
Change From Baseline in Fasting LDL-C at Week 48
Time Frame: Baseline (Day 1) and Week 48
|
The mean percent change from baseline in fasting (fast duration of ≥8 hours) LDL-C levels at Week 48 was determined for each arm.
The Last Observation Carry Forward (LOCF) approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
|
Baseline (Day 1) and Week 48
|
Change From Baseline in Fasting Non-HDL-C at Week 48
Time Frame: Baseline (Day 1) and Week 48
|
The mean percent change from baseline in fasting (fast duration of ≥8 hours) non-HDL-C levels at Week 48 was determined for each arm.
The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
|
Baseline (Day 1) and Week 48
|
Change From Baseline in Fasting Cholesterol at Week 48
Time Frame: Baseline (Day 1) and Week 48
|
The mean percent change from baseline in fasting (fast duration of ≥8 hours) cholesterol levels at Week 48 was determined for each arm.
The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
|
Baseline (Day 1) and Week 48
|
Change From Baseline in Fasting Triglycerides at Week 48
Time Frame: Baseline (Day 1) and Week 48
|
The mean percent change from baseline in fasting (fast duration of ≥8 hours) triglycerides levels at Week 48 was determined for each arm.
The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
|
Baseline (Day 1) and Week 48
|
Change From Baseline in Fasting HDL-C at Week 48
Time Frame: Baseline (Day 1) and Week 48
|
The mean percent change from baseline in fasting (fast duration of ≥8 hours) HDL-C levels at Week 48 was determined for each arm.
The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
|
Baseline (Day 1) and Week 48
|
Percentage of Participants With HIV-1 RNA Below the Limit of Quantification (BLoQ) at Week 48
Time Frame: Week 48
|
The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 48 was determined.
Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay.
Data were handled as observed.
|
Week 48
|
Percentage of Participants With HIV-1 RNA BLoQ at Week 96
Time Frame: Week 48
|
The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 96 will be determined.
Plasma HIV RNA levels will be quantified with the Abbott RealTime HIV-1 Assay.
Data will be handled as observed.
|
Week 48
|
Plasma Concentration of Doravirine at Week 48
Time Frame: 0 hours post-dose and 2 hours post-dose on Week 48
|
Plasma samples were collected for analysis of doravirine concentration at Week 48.
A total of 2 samples were collected: 1 prior to dosing and 1 collected between 0.5 and 2 hours post-dose.
|
0 hours post-dose and 2 hours post-dose on Week 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Orkin C, Squires KE, Molina JM, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ, Hwang C, Martin E, Teppler H. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Clin Infect Dis. 2021 Jul 1;73(1):33-42. doi: 10.1093/cid/ciaa822.
- Orkin C, Molina JM, Lombaard J, DeJesus E, Rodgers A, Kumar S, Martin E, Hanna G, Hwang C. Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clin Infect Dis. 2020 Mar 17;70(7):1344-1352. doi: 10.1093/cid/ciz424. Erratum In: Clin Infect Dis. 2020 Jan 2;70(2):360.
- Thompson M, Orkin C, Molina JM, Sax P, Cahn P, Squires K, Xu X, Rodgers A, Kumar S, Teppler H, Martin E, Hanna G, Hwang C. Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis. Clin Infect Dis. 2020 Mar 17;70(7):1336-1343. doi: 10.1093/cid/ciz423.
- Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA; DRIVE-AHEAD Study Group. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019 Feb 1;68(4):535-544. doi: 10.1093/cid/ciy540.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 5, 2015
Primary Completion (Actual)
March 20, 2017
Study Completion (Actual)
September 7, 2023
Study Registration Dates
First Submitted
March 26, 2015
First Submitted That Met QC Criteria
March 26, 2015
First Posted (Estimated)
March 31, 2015
Study Record Updates
Last Update Posted (Estimated)
October 9, 2023
Last Update Submitted That Met QC Criteria
September 22, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
- Lamivudine
- Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Other Study ID Numbers
- 1439A-021
- MK-1439A-021 (Other Identifier: Merck Protocol Number)
- 2014-003382-17 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus (HIV)
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
RTI InternationalCenters for Disease Control and PreventionCompletedHuman Immunodeficiency Virus (HIV) PositiveUnited States
-
Bristol-Myers SquibbCompleted
-
Merck Sharp & Dohme LLCRecruitingHuman Immunodeficiency Virus (HIV) InfectionUnited States, Mexico, Russian Federation, South Africa, Thailand
-
Janssen-Cilag International NVCompletedHuman Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) VirusFrance, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
-
Janssen Inc.CompletedHuman Immunodeficiency Virus (HIV)Canada
-
Auritec PharmaceuticalsEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHuman Immunodeficiency Virus (HIV) ProphylaxisUnited States
-
Columbia UniversityNational Institute of Allergy and Infectious Diseases (NIAID); New York University and other collaboratorsCompletedHIV (Human Immunodeficiency Virus)Swaziland
-
Columbia UniversityMinistry of Health, SwazilandCompleted
Clinical Trials on Doravirine, Tenofovir, Lamivudine
-
Merck Sharp & Dohme LLCCompletedHIV-1 InfectionUnited States, Chile, France, United Kingdom
-
Merck Sharp & Dohme LLCCompleted
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingHIV InfectionsUnited States
-
Professor Francois VenterRecruiting
-
Professor Francois VenterCompleted
-
ANRS, Emerging Infectious DiseasesMSD FranceNot yet recruitingHIV-1-infectionBrazil, Cambodia, Cameroon, Côte D'Ivoire, France, Mozambique
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States, South Africa, Thailand
-
Lee's Pharmaceutical LimitedUnknownAcquired Thrombotic Thrombocytopenic PurpuraChina
-
Qpex Biopharma, Inc.Biomedical Advanced Research and Development AuthorityCompletedBacterial InfectionsUnited States